These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34342108)

  • 41. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
    Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ;
    Lancet Oncol; 2015 Aug; 16(8):928-36. PubMed ID: 26115797
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
    Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
    Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
    Brackmann M; Stasenko M; Uppal S; Erba J; Reynolds RK; McLean K
    BMC Cancer; 2018 Feb; 18(1):172. PubMed ID: 29426293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
    Shi T; Jiang R; Pu H; Yang H; Tu D; Dai Z; Cai Y; Zhang Y; Cheng X; Jia H; Tu R; Wang H; Tang J; Luan Y; Cai S; Zang R;
    Br J Cancer; 2019 Aug; 121(5):425-428. PubMed ID: 31383985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.
    Mardas M; Stelmach-Mardas M; Madry R
    Support Care Cancer; 2017 Mar; 25(3):795-800. PubMed ID: 27771784
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
    Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
    Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
    Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
    Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
    Sorbe B; Graflund M; Nygren L; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
    Int J Oncol; 2012 Mar; 40(3):773-81. PubMed ID: 22159569
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
    van Driel WJ; Koole SN; Sikorska K; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AGJ; Verwaal VJ; Kieffer JM; Van de Vijver KK; van Tinteren H; Aaronson NK; Sonke GS
    N Engl J Med; 2018 Jan; 378(3):230-240. PubMed ID: 29342393
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
    Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
    Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Taxanes in combination with platinum derivatives for the treatment of ovarian cancer during pregnancy: A literature review
.
    Zheng X; Zhu Y; Zhao Y; Feng S; Zheng C
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):753-760. PubMed ID: 28737125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
    Lawrie TA; Rabbie R; Thoma C; Morrison J
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
    Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
    Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.
    Machida H; Tokunaga H; Matsuo K; Matsumura N; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Mikami M
    Eur J Surg Oncol; 2020 May; 46(5):868-875. PubMed ID: 31818526
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy.
    Nishikawa A; Hashimoto H; Takeda M; Kontani K; Miyatake T; Mimura M; Nagamatsu M; Yokoi T
    Eur J Gynaecol Oncol; 2016 Aug; 37(4):451-454. PubMed ID: 29894065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Maheshwari A; Kumar N; Gupta S; Rekhi B; Shylasree TS; Dusane R; Bajpai J; Ghosh J; Gulia S; Deodhar K; Menon S; Popat P; Sable N; Thakur M; Kerkar R
    Indian J Cancer; 2018; 55(1):50-54. PubMed ID: 30147093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.